Neurofibromatosis

Renowned Surgeon, Researcher, and Educator in Robotic Surgery of the Head and Neck Joins NYU Langone Health as New Chair of Otolaryngology

Retrieved on: 
Thursday, June 29, 2023
University, Moses Austin, Neurotology, NYU, New York University Grossman School of Medicine, Neurofibromatosis, Human, Research, Doctor of Philosophy, Neck, Bangladesh Technical Education Board, NYU Langone Health, University of Pittsburgh Medical Center, Cell biology, Patent, Patient, Division, Veterans' affairs, MD Anderson Cancer Center, Paralysis, Wilfrid Sellars, NIH, Dentistry, Nursing, Head, MD, Otorhinolaryngology

He joins the institution from the University of Pittsburgh School of Medicine, where he served as a professor in the Departments of Otolaryngology and Cell Biology, director of robotic surgery in the Division of Head and Neck Surgery, and co-leader of the Head and Neck Cancer Program.

Key Points: 
  • He joins the institution from the University of Pittsburgh School of Medicine, where he served as a professor in the Departments of Otolaryngology and Cell Biology, director of robotic surgery in the Division of Head and Neck Surgery, and co-leader of the Head and Neck Cancer Program.
  • Dr. Duvvuri has made significant innovations in the field of head and neck surgery , advancing robotic surgery to perform complex and precise procedures that simultaneously minimize patient impact.
  • Dr. Duvvuri holds a patent on a novel tactile feedback system for robotic surgery.
  • "An innovator in the field of head and neck surgery, Dr. Duvvuri has significantly advanced robotic surgery to perform complex and precise procedures that maximize patient outcomes while lessening detrimental side effects," said Robert I. Grossman, MD, dean and CEO of NYU Langone Health.

Jason Colodne and Colbeck Capital Sponsor The Children's Tumor Foundation NF Summit 2023

Retrieved on: 
Tuesday, June 20, 2023
Finance, Fund Raising, Foundation, Professional Services, Philanthropy, Volunteering, CTF, NF, Education, Cerberus Capital Management, Neoplasm, Deafness, Cancer, Neurofibromatosis, Research, Paratriathlon, Learning, Patient, Schwannomatosis, Nervous system, Motivation, Knowledge, Empowerment, Conference, Disease, Pharmaceutical industry

Colbeck Capital Management (“Colbeck”) today announced its continued support of the Children’s Tumor Foundation (“CTF” or the “Foundation”) through sponsorship of the CTF NF Summit 2023, which will be held from June 21st through June 24th in Scottsdale, Arizona.

Key Points: 
  • Colbeck Capital Management (“Colbeck”) today announced its continued support of the Children’s Tumor Foundation (“CTF” or the “Foundation”) through sponsorship of the CTF NF Summit 2023, which will be held from June 21st through June 24th in Scottsdale, Arizona.
  • This year’s NF Summit features an all-inclusive format that merges the NF Forum and the Volunteer Leadership Conference, allowing supporters like Jason Colodne and Colbeck to customize their agendas to explore content relevant to them and their NF journey, whether they attend in-person or virtually.
  • The atmosphere will be energetic, interactive, and enriching with access to experts in NF.
  • CTF is committed to hosting events like the NF Summit to promote awareness and funding for its mission to end NF, a group of genetic conditions that causes tumors to form throughout the nervous system.

Pasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis Conference

Retrieved on: 
Thursday, June 1, 2023
Medical school, Indiana University, NF, Central nervous system, PALO, Research, MEK, CNS, Model, Neurofibroma, KTTA, School, Conference, Neurofibromatosis, Pharmaceutical industry

PALO ALTO, Calif. and MIAMI, June 01, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, today announced that pre-clinical results for its lead drug candidate, PAS-004, have been accepted for a poster presentation at the 2023 Neurofibromatosis (NF) Conference taking place June 24-27, 2023, in Scottsdale, Arizona.

Key Points: 
  • PALO ALTO, Calif. and MIAMI, June 01, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, today announced that pre-clinical results for its lead drug candidate, PAS-004, have been accepted for a poster presentation at the 2023 Neurofibromatosis (NF) Conference taking place June 24-27, 2023, in Scottsdale, Arizona.
  • “We are extremely pleased to be presenting preclinical data from PAS-004 conducted in collaboration with Dr. Wade Clapp at Indiana University, School of Medicine,” commented Dr. Graeme Currie, Pasithea’s Chief Development Officer.
  • “The presentation will provide insight into PAS-004 efficacy and support further development of our lead candidate.”
    Findings will be shared on a poster entitled “Evaluation of the Effects of a Novel MEK inhibitor PAS-004 in Plexiform Neurofibroma in a Pre-clinical Mouse Model of Neurofibromatosis Type 1”.
  • Poster will be available to view during the 2023 NF Conference on the evening of Sunday, June 25th, from 5:00pm - 7:00pm.

Children's Tumor Foundation Announces Start of NF Awareness Month with Make NF Visible Campaign

Retrieved on: 
Monday, May 1, 2023
Lighting, Make, CTF, NF, Children's Tumor Foundation, Waterfall, Life, Neoplasm, Empire State Building, Neurofibromatosis, Human, Research, Empire, Photography, WIBW, Community, Patient, Collection, Schwannomatosis, Shine a Light, Northern Lights, Diagnosis, City, Disease, Medical imaging, Entertainment, Computer data storage

NEW YORK, May 1, 2023 /PRNewswire/ -- May is NF Awareness Month and the Children's Tumor Foundation is excited to release a new class of inspiring patient stories for the Make NF Visible campaign. NF is a group of genetic conditions known as neurofibromatosis or schwannomatosis that cause tumors to grow on nerves throughout the body. NF affects all populations equally, but it manifests differently in each patient; patients with visible signs of NF struggle to be seen as more than just their NF, while patients whose NF is internal, or 'invisible,' struggle to make others understand. NF Awareness Month is an opportunity to amplify the voice of all NF patients through the 'Make NF Visible' initiative.

Key Points: 
  • 31 Days to Make NF Visible, get involved, and drive research for rare genetic condition that affects millions people worldwide and has no cure
    NEW YORK, May 1, 2023 /PRNewswire/ -- May is NF Awareness Month and the Children's Tumor Foundation is excited to release a new class of inspiring patient stories for the Make NF Visible campaign.
  • NF Awareness Month is an opportunity to amplify the voice of all NF patients through the 'Make NF Visible' initiative.
  • World NF Awareness Day, May 17, will culminate with the 4th annual Make NF Visible: A World NF Day Live Event.
  • For more information on the Children's Tumor Foundation, as well as all NF Awareness Month campaign initiatives, please visit makenfvisible.org.

Colbeck Capital Sponsors Children’s Tumor Foundation in 2023 TD Five Boro Bike Tour to Increase Awareness of and Fundraising for Foundation to End Neurofibromatosis

Retrieved on: 
Monday, May 1, 2023
Sports, Consulting, Banking, Professional Services, Health, Philanthropy, Other Philanthropy, Neurology, Foundation, Biking, Cycling, Finance, CTF, NF, TD, Highland Capital Management, Neoplasm, Deafness, Cancer, Five Boro Bike Tour, Neurofibromatosis, Research, Paratriathlon, Attention, Learning, Schwannomatosis, Nervous system, Knowledge, Environment, Road

Colbeck Capital Management (“Colbeck”) today announced its continued support of the Children’s Tumor Foundation (“CTF” or the “Foundation”) through its sponsorship of the NF Endurance Team in the upcoming TD Five Boro Bike Tour, presented by Bike New York.

Key Points: 
  • Colbeck Capital Management (“Colbeck”) today announced its continued support of the Children’s Tumor Foundation (“CTF” or the “Foundation”) through its sponsorship of the NF Endurance Team in the upcoming TD Five Boro Bike Tour, presented by Bike New York.
  • CTF is committed to events like TD Five Boro Bike Tour to promote awareness of and fundraising for its mission to end NF, a group of genetic conditions that causes tumors to form throughout the nervous system.
  • The tour also brings awareness to the need for safer biking accommodations throughout the city and promotes safe cycling practices for participants.
  • The 45th annual event requires preregistration to attend, and a portion of the registration cost is tax deductible as a charitable donation.

Researchers Report Clinical Proof-of-Concept Data for Vivace Therapeutics' VT3989, a First for a Cancer Drug Targeting the Hippo Pathway, in Oral Presentation at AACR 2023

Retrieved on: 
Sunday, April 16, 2023
Molecule, Extremities, Human, AACR, University, NF2, American Association for Cancer Research, Urine, Alanine transaminase, Neoplasm, YAP, Neurofibromatosis, Trial of the century, Mesothelioma, MD Anderson Cancer Center, TEAD, Plasma, Sarcoma, Merlin, Patient, Swelling, SAN, Article, Albuminuria, Nausea, Biology, Pulmonary toxicity, Therapy, Hippopotamus, News, Molecular Cancer Research, Fatigue, Pharmaceutical industry, Medical imaging

SAN MATEO, Calif., April 16, 2023 /PRNewswire/ -- Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, today announced that the first clinical data for a cancer treatment targeting the Hippo pathway was presented at the American Association for Cancer Research (AACR) Annual Meeting 2023. Results from the company's Phase 1 clinical study of its first-in-class transcriptional enhanced associate domain (TEAD) autopalmitoylation inhibitor, VT3989, showed the compound to be well tolerated with durable antitumor responses in patients with advanced malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations. These findings were presented by Timothy A. Yap, M.D., Ph.D., of The University of Texas MD Anderson Cancer Center, during an oral plenary session at the conference. The AACR conference is being held April 14-19, 2023, in Orlando, Florida.

Key Points: 
  • The AACR conference is being held April 14-19, 2023, in Orlando, Florida.
  • Tumor response was observed in patients with mesothelioma with and without NF2 mutations and other solid tumors with NF2 mutations.
  • Because mesothelioma patients often have NF2 mutations or loss of Merlin it was an a priori indication of interest.
  • "Preclinical data suggested that blocking the YAP-TEAD interaction could shrink tumors, and these clinical data validate that approach.

Children's Hospital of Philadelphia Receives $10 Million Grant from the Gilbert Family Foundation to Accelerate Neurofibromatosis Research

Retrieved on: 
Tuesday, April 4, 2023
LGG, NF, Brain, Executive, Gene, CHOP, Prevalence, Genetics, Neuro-Oncology (journal), Elective surgery, Pediatrics, Neoplasm, Section, Heredity, HGAP, Hope, Neurofibromatosis, Research, Immunotherapy, VRI, Pain, CAR, Disorder, Neuro-ophthalmology, Genetic disorder, Standard of care, Patient, Investment, Neuro-oncology, HGG, Ophthalmology, Infant, Paratriathlon, NF1, Family, Neurology, BTI, Vision restoration therapy, Disease, Medical imaging, Pharmaceutical industry

PHILADELPHIA, April 4, 2023 /PRNewswire/ -- Children's Hospital of Philadelphia (CHOP) today announced that it has received more than $10 million in a series of gifts to fund critical neurofibromatosis research from the Gilbert Family Foundation, a private foundation established by Dan and Jennifer Gilbert to accelerate a cure for neurofibromatosis type 1 (NF1). 

Key Points: 
  • The tumors that develop in the brain and body can lead to serious complications, including vision loss and severe pain.
  • The Gilbert Family Foundation was founded in 2015 to help accelerate a cure for NF1.
  • Nick Gilbert, the oldest son of Dan and Jennifer Gilbert, was diagnosed with NF1 as an infant and continues to battle the disease.
  • CHOP has received previous investments for its promising research as part of the Gilbert Family Foundation's Vision Restoration Initiative (VRI).

PCORI approves $123 million for research on postpartum care, hypertension management, antibiotic prescribing and a range of conditions

Retrieved on: 
Tuesday, March 28, 2023
Asthma, Hearing loss, CER, Patient-Centered Outcomes Research Institute, Health equity, Neurofibromatosis, Research, Rehabilitation, Hypertension, Work, Patient, PCORI, Colorectal cancer, Machine learning, National Priorities List, Peripheral artery disease, MPH, Birth control, Pharmaceutical industry, Nursing, Medical device, Health

WASHINGTON, March 28, 2023 /PRNewswire/ -- The Patient-Centered Outcomes Research Institute (PCORI) today announced funding awards totaling $123 million to support 15 new research studies. These studies aim to fill evidence gaps, enhance research methods, or improve health care decision making for a range of high-burden concerns among adults and children, including postpartum complications occurring in populations experiencing the greatest disparities in health outcomes.

Key Points: 
  • WASHINGTON, March 28, 2023 /PRNewswire/ -- The Patient-Centered Outcomes Research Institute (PCORI) today announced funding awards totaling $123 million to support 15 new research studies.
  • This research also will contribute data and strategies to help achieve health equity, one of PCORI's National Priorities for Health."
  • All funding awards were approved pending a business and programmatic review by PCORI staff and the issuance of formal award contracts.
  • With these latest awards, PCORI has invested approximately $4 billion to fund patient-centered CER and other research-related projects.

Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004

Retrieved on: 
Wednesday, January 18, 2023
IND, API, Neurofibromatosis, Clinical trial, MEK inhibitor, CMC, CNS, MIAMI, NF1, FDA, Research, Central nervous system, Contract manufacturing organization, Wuxi, STA, Chemistry, KTTA, GMP, Pharmaceutical industry, Fine chemical

MIAMI BEACH, Fla., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of innovative treatments for Central Nervous System (CNS) disorders, today announced its contract with WuXi STA, a subsidiary of WuXi AppTec, to manufacture the active pharmaceutical ingredient (“API”) for Pasithea’s macrocyclic, next-generation MEK Inhibitor, PAS-004 (formerly CIP-137401).

Key Points: 
  • WuXi STA is recognized as an industry leader in “end-to-end” chemistry, manufacturing, and controls (CMC) services, for both API and finished dosage forms, with extensive expertise and track record for meeting global quality standards.
  • “​We are delighted to be working with WuXi STA, one of the largest and most well-respected Contract, Development, and Manufacturing Organizations (CDMOs) in the world.
  • We remain on track with PAS-004 development and look forward to our IND submission followed by the initiation of our Phase 1 clinical trial,” commented Pasithea CEO, Dr. Tiago Reis Marques.
  • “WuXi STA has a proven track record of manufacturing success to FDA standards and we believe that their high-quality capabilities will support progression of our drug candidate into the clinic.

In Honor of Penny Doerge, the Doerge Family Announces the Launch of Penny’s Flight, a Foundation Dedicated to Raising Awareness and Funding Research for Neurofibromatosis and Related Disorders

Retrieved on: 
Thursday, January 5, 2023
Research, Neurology, Genetics, Philanthropy, Other Health, Fund Raising, Health, Foundation, Science, Oncology, Treasurer, Brain, NF, Disorder, NF1, Fear, Research, Knowledge, Disease, Face, Neurosurgery, Patient, Orthopedic surgery, Chief Medical Advisor to the President, Chad, Hospital for Special Surgery, Butterfly, Genetic disorder, Parent, Hospital, Pharmaceutical industry, Child, Neurofibromatosis

NF1, which can affect people in a wide variety of ways, is the most common genetic disorder globally and still has no cure.

Key Points: 
  • NF1, which can affect people in a wide variety of ways, is the most common genetic disorder globally and still has no cure.
  • Penny’s Flight Foundation is established in celebration of the extraordinary life and the inspirational qualities that Penny Doerge personified — joy, artistic expression, and humor — while bravely living with Neurofibromatosis since infancy.
  • The Foundation’s mission is to make much-needed advances in medical research on Neurofibromatosis and related disorders — with a lasting impact on altering the course of this disease.
  • The foundation board is composed of Chad Doerge (Chair), Kate Doerge, (Vice Chair and President), Megan Grant (Secretary), and Scott Willard (Treasurer).